Waleed H Hassanein has bought TMDX on 2 days since Aug 2025
President and CEO at TransMedics Group, Inc.
SEC CIK 0001430466 · Filings on SEC.gov ↗
Waleed H Hassanein's record
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Every filing
36 filings since Mar 2021, newest first
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
Transmedics Group, Inc.
President and CEO
About Waleed H Hassanein
Waleed H. Hassanein, M.D. is the founder, President, Chief Executive Officer, and Director of TransMedics Group, Inc. (TMDX), a medical technology company specializing in organ transplant systems, which he established in August 1998.( Under his leadership, the company has achieved significant growth, with 2024 revenue reaching $441.5 million (up 83% year-over-year), positive operating profit of $37.5 million, net income of $35.5 million, and positive cash flow from operations for the first time.(
Hassanein earned his M.D. from Georgetown University in 1993, completed a 2-year general surgery residency at Georgetown University Medical Center, and undertook a 3-year cardiac surgery research fellowship at West Roxbury VA Medical Center and Brigham and Women’s Hospital (Harvard affiliate).( His innovations in organ preservation technology, including patented systems for warm blood perfusion to maintain organs outside the body for heart, lung, liver, and kidney transplants, have driven TransMedics' advancements.( As a corporate insider, he has recently engaged in stock transactions, including a purchase of 16,875 shares on August 8, 2025, and holds approximately 616,433 shares valued over $84 million.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.